drugset / Trial / NCT04514419
Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel
RandomizedParallel-groupDouble-blindTreatment
Summary
The trial included screening period (4 weeks) and treatment period (4 treatment cycles, at least 12 weeks).
Timeline
- Start
- 2020-06-28
- Primary completion
- 2024-09-11
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HS627 | Monoclonal antibody | — | — |
| Subject | Pertuzumab | Monoclonal antibody | — | — |
| Background | Docetaxel | Small molecule | — | — |
| Background | Trastuzumab | Monoclonal antibody | — | — |